1008 related articles for article (PubMed ID: 30649742)
1. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
[TBL] [Abstract][Full Text] [Related]
2. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
6. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
7. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
8. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
9. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
10. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.
Zhang JC; Chen WD; Alvarez JB; Jia K; Shi L; Wang Q; Zou N; He K; Zhu H
Acta Pharmacol Sin; 2018 Nov; 39(11):1693-1698. PubMed ID: 29991709
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
Azoury SC; Straughan DM; Shukla V
Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Toxicity.
Mantia CM; Buchbinder EI
Hematol Oncol Clin North Am; 2019 Apr; 33(2):275-290. PubMed ID: 30833000
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of response to PD-1/PD-L1 inhibition.
Maleki Vareki S; Garrigós C; Duran I
Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
15. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
16. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
Sun R; Champiat S; Dercle L; Aspeslagh S; Castanon E; Limkin EJ; Baldini C; Postel-Vinay S; Hollebecque A; Massard C; Ammari S; Deutsch E; Soria JC; Marabelle A; Ferté C
Eur J Cancer; 2017 Oct; 84():202-211. PubMed ID: 28826073
[TBL] [Abstract][Full Text] [Related]
17. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
18. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
Chow LQ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.
Zhang N; Tu J; Wang X; Chu Q
Immunotherapy; 2019 Apr; 11(5):429-441. PubMed ID: 30698054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
